|
|
|
Agenda
Day One - February 12
|
8:00am |
Registration |
|
9:00am |
Clinical Perspectives - Session Chair: Anders Haegerstrand, President and CEO, Neuronova |
|
|
Clinical Use of Adipose-Derived Stem Cells in Over 2,000 Orthopedic Cases in the Equine and Canine
Robert Harman, CEO, VetStem Inc.
Adult stem cell therapy is in use treating orthopedic injuries in animals. This presentation summarizes the clinical, regulatory, and business experiences of a veterinary regenerative medicine company, with data from 2000 commercial cases treated with adipose-derived stem cells. |
|
|
Retinal Repair by Transplantation of Photoreceptor Precursors
Robin Ali, Professor, University College London |
|
|
Coffee & networking in exhibition hall |
|
|
Keynote Address - The Biopolitical and Therapeutic Landscape of Stem Cell Research
Stephen Minger, Director, Stem Cells Biology Laboratory, King’s College |
|
|
Transplants of Human Embryonic Stem Cells (HESC) Improved Motor Function recovery in Spinal Cord Injured Rats
Jay Sharma, CEO & CSO, Celprogen
Human Embryonic Stem Cells (HESC) derived from Amniotic membrane / fluid represent a potentially useful source of stem cells for cell replacement therapy after nervous tissue damage. The HESCs can be maintained and expanded in Celprogen’s HESC matrix and serum free media tissue culture system without losing their stem cell characteristics (stemness). These HESCs once expanded in culture can be re-introduced into patients as auto-grafts or allo-grafts. In preclinical transplant studies with embryonic stem cells, various investigators have demonstrated both safety as a source for neurons for transplantation and efficacy in treating stroke-related behavioral deficits. |
|
|
The Cornea as a Model for Stem Cell Niche Characterisation and Therapy
Julie Daniels, Lecturer, University College London
Transparency of the cornea, and therefore vision, is dependent upon functional limbal epithelial stem cells (LESC) which maintain the corneal epithelium. Depletion of LESC results in painful, blinding ocular surface disease. This presentation will discuss how our understanding of the LESC niche will improve therapeutic ex-vivo expansion and transplantation of autologous (and allogeneic) LESC. |
| 12:35pm |
Lunch & poster viewing |
|
2:05pm |
Stem Cell Biology - Part One - Session Chair: Robin Ali, Professor, University College London |
|
2:10pm |
Adult Neural Crest Stem Cells from Hair Follicles
Maya Sieber-Blum, Professor, Medical College of Wisconsin
Epidermal neural crest stem cells (EPI-NCSC) are a novel type of multipotent adult stem cell. They are remnants of the embryonic neural crest that reside in the bulge of hair follicles and can be isolated as a highly pure population. |
|
2:40pm |
Keynote Address - Stem Cells in the Adult Nervous System
Fred Gage, Professor/Staff Scientist, Salk Institute
The Salk Institute has recently identified several novel mechanisms that regulate proliferation, survival and differentiation of adult derived stem cells. The functional and practical significance of these findings will be discussed in light of their implications for alternative or expanded views of structural plasticity in the adult brain. |
| 3:25pm |
Coffee & networking in exhibition hall |
|
4:10pm |
Self-renewal of Embryonic Stem Cells
Thomas Zwaka, Assistant Professor, Baylor College of Medicine
Our current investigations are focused on determining how undifferentiated embryonic stem cells decide when to undergo programmed cell death and when to differentiate. |
| 4:40pm |
Definition and Manipulation of the Hematopoietic Stem Cell Niche
Gregor Adams, Instructor, Massachusetts General Hospital
Understanding the microenvironmental niche and the intracellular signals that allow for expansion of stem cells during development will have therapeutic potential. We have identified key components of the hematopoietic stem cell niche and further demonstrated that these can be targeted to enhance therapies aimed at the stem cells. |
| 5:10pm |
Innovations in Stem Cell Culture
Steven Sheridan, Group Leader, Millipore |
|
5:40pm |
Drinks reception in exhibition hall |
Back to top
Day Two - February 13
| 9:00am |
Stem Cell Biology - Part Two - Session Chair: Gregor Adams, Instructor, Massachusetts General Hospital |
|
9:05am |
Isolation and Modulation of Neural Precursors and Stem Cells from the Mammalian Enteric Nervous System
Thomas Skutella, Group Leader, University of Tuebingen |
|
9:35am |
Keynote Address - Biologics for Stem Cells Rather than Stem Cells as Biologics - Opportunities and Risks
Anders Haegerstrand, President and CEO, Neuronova
Stem cells as an infinite source of cells for transplantation purposes is attractive but poses significant challenges when transferred from rodent cells and the lab bench to human cells for product development. Developing drugs to be delivered systemically or locally to stem cell nieches that promote regenerative processes, represents a promising route for "stem cell based therapies". If successful these opportunities will be more attractive from a product development perspective. Such efforts including pros and cons will be reviewed. |
|
10:05am |
Coffee & networking in exhibition hall |
|
10:50am |
MSC-based Approaches to Skeletal Repair: From Bench to Bedside
Cosimo De Bari, Senior Lecturer, King’s College
We have identified and characterized mesenchymal stem cells (MSCs) from the adult human synovial membrane. We are currently investigating their niche(s) in vivo to develop technologies to activate and direct the resident MSCs to achieve joint surface repair. |
|
11:20am |
Keynote Address - Characterization of ESC
Mahendra Rao, VP Research – Stem Cells and Regenerative Medicine, Invitrogen |
|
12:05pm |
Lunch & poster viewing |
|
1:35pm |
Commercial Applications of Stem Cell Research - Session Chair: Mahendra Rao, VP Research - Stem Cells and Regenerative Medicine, Invitrogen |
|
1:40pm |
Using STR DNA Markers for Positive Identification of Stem Cell Lines
Mario Salguero, Director of Molecular Diagnostics, Cell Line Genetics |
|
2:10pm |
Multi-lineage Progenitor Cells (MLPC) an Umbilical Cord Blood-Derived Multi-potent Stem Cell that Arises from an Adherent CD45+/CD34+/CD9+ Subset
Dan Collins, CSO, BioE
Description of a new and unique multi-potent stem cell derived from post-partum human umbilical cord blood. Methods of isolation, characterization, and differentiation are described. The development of stable, clonal cell lines is shown. Interactions of MLPC with surface environments and extracellular matrices is discussed with regards to differentiation and tissue engineering. |
|
2:40pm |
A New Pluirpotent Human Stem Cell Platform Grown Directly on Plastic, Scalable for use in Many Different Drug Discovery Applications
James Kelly, CEO, Stem Cell Innovations |
|
3:10pm |
Coffee & networking in exhibition hall |
|
3:55pm |
Embryonic Stem Cells: Tools for Drug Discovery and Development
Ralph Snodgrass, CEO, VistaGen Therapeutics |
|
4:25pm |
Current Requirements for Manufacturing Stem Cells for Clinical Trials
Alan Smith, President and COO, Cognate Bioservices
This talk will address the challenges of growing stem cells to production scale under cGMPs to meet human clinical trial and commercialization needs. |
|
4:55pm |
Close of conference | |